Effector Therapeutics

Open enrollment with an early-phase pipeline tilt

According to ClinicalTrials.gov-derived indexes, Effector Therapeutics sits in the top decile of US sponsors by registered trial count (#1,458 of 15,742 sponsors by registered trial count).

9 total trials 1 currently recruiting 3 completed early-phase tilt top decile by trial count

Effector Therapeutics: 9 sponsored US clinical trials, 1 recruiting.

Effector Therapeutics sponsors 9 registered US clinical trials on ClinicalTrials.gov, 1 of them currently recruiting, and 3 completed. 0 of these trials are in Phase 3-4 (later-stage) and 9 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is Solid Tumor, Adult, with 1 trials.

Top-decile sponsor footprint

Effector Therapeutics ranks in the top decile of sponsors by registered trial count (#1,458 of 15,742 sponsors by registered trial count). Volume at this scale usually reflects a long institutional pipeline, read phase tilt and therapeutic areas below before treating it as current-year activity.

Open and recent trials

9 total, page 1 of 1

RECRUITING Phase 1

Study of eFT226 in Subjects With Selected Advanced Solid Tumor Malignancies

NCT04092673
ACTIVE NOT RECRUITING Phase 2

Tomivosertib Combined With Pembrolizumab in Subjects With PD-L1 Positive NSCLC (KICKSTART)

NCT04622007
COMPLETED Phase 1

Intravenous Zotatifin in Adults With Mild or Moderate COVID-19

NCT04632381
TERMINATED Phase 2

An Open-label Study of the Effect of Tomivosertib (eFT508) in Patients With Advanced Castrate-resistant Prostate Cancer

NCT03690141
COMPLETED Phase 2

Tomivosertib (eFT-508) in Combination With PD-1/PD-L1 Inhibitor Therapy

NCT03616834
TERMINATED Phase 2

A PD Study of Oral eFT508 in Subjects With Advanced TNBC and HCC

NCT03318562
COMPLETED Phase 2

A Study to Evaluate eFT508 Alone and in Combination With Avelumab in Subjects With MSS Colorectal Cancer

NCT03258398
TERMINATED Phase 1

A Phase 1-2 Dose-Escalation and Cohort-Expansion Study of Oral Tomivosertib (eFT-508) in Subjects With Hematological Malignancies

NCT02937675
TERMINATED Phase 1

A Dose Escalation and Cohort-Expansion Study of Oral eFT508 in Subjects With Advanced Solid Tumors

NCT02605083

Phase Distribution

PhaseTrial count
Phase 1 4
Phase 2 5

Therapeutic Areas

Solid Tumor, Adult 1
Non-Small Cell Lung Cancer 1

What is open in the Effector Therapeutics pipeline

1 recruiting of 9 indexed (11% open); 3 completed (33%).

Phase mix: 0 late (III/IV) vs 9 early (I/II) (early-phase heavy).

Top condition: Solid Tumor, Adult (1 trial), 1 other listed.

How open-pipeline share is computed

Recruiting share is recruiting_count divided by trial_count for this sponsor in the public registry export. Status can change between pulls; treat the figure as a research-attention snapshot, not product availability.

Effector Therapeutics: open-pipeline peers nationwide

Peers matched on 9 registered trials and 11% open enrollment, not the therapeutic-area sidebar.

Effector Therapeutics sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together. Source: ClinicalTrials.gov (2026-08-08 snapshot). 2×2 strategic matrix plotting 9 entities by Total trials (X) and Recruiting share (Y), with a crosshair dividing the plot into four quadrants. Higher volume & more openFocused & more openHigher volume, mostly closedSmaller & mostly closed 01020304050 0%10%20%30%40%50% Total trials Recruiting share Effector Therapeutics4D Molecular Therapeutics9 Meters BiopharmaAadi BioscienceAblynx, a Sanofi companyADC Therapeutics S.A.Adrian VellaAIDS Malignancy ConsortiumAmylyx Pharmaceuticals
Effector Therapeutics sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together. Source: ClinicalTrials.gov (2026-08-08 snapshot).

Effector Therapeutics sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together.

Sponsors near 9 trials (± recruiting share)

Sponsors near 11% open enrollment (± trial volume)

Related

Read our methodology - how this data is sourced, computed, and verified.

What to do with this Effector Therapeutics page

9 registered trials is a research-attention snapshot, not an endorsement of Effector Therapeutics or any single study.

  • 1 of Effector Therapeutics's trials are currently recruiting, check each one's own eligibility criteria before contacting a site. Browse recruiting trials
  • Solid Tumor, Adult is the condition Effector Therapeutics studies most, compare against other sponsors active in the same condition before evaluating a specific study. See Solid Tumor, Adult trials
  • Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide

Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.

Effector Therapeutics pipeline card: 9 registered trials from official public datasets.Report a data error.